NatiVita explained

NatiVita
Type:Public
Foundation:2012
Industry:Innovative medications research and developing

NatiVita is an international research and manufacturing pharmaceutical company, it is situated in Beshankovichy urban settlement, Vitebsk region, Belarus. NatiVita is the first company in Belarus, that started developing and producing biopharmaceutical medicines based on monoclonal antibodies using target cell therapy for specific genetic diseases such as Breast cancer, Lung cancer, Myeloma.[1] The company was established in 2012 with support of AB ZiaValda[2] (Lithuania), «UniPharma» (Slovakia), «NatcoPharma Ltd» (India)

Pharmaceutical producing complex

Pharmaceutical producing complex NatiVita has a full cycle of medicine's production according to the European quality standard GMP[3]

Scientific-research centre

The International Scientific-research centre Nativita was opened in 2017.[4]

External links

Notes and References

  1. http://schneider-group.com/wp-content/uploads/2017/03/SCHNEIDER_GROUP_Pharmaceutical_Industry_Insights_Report.pdf Pharmaceutical Industry in Russia, Ukraine, Belarus and Kazakhstan
  2. http://www.ziavalda.lt/en/page/pharmacy-nativita The company was established in 2012 with support of AB ZiaValda
  3. Web site: Archived copy . 2017-08-09 . 2017-08-09 . https://web.archive.org/web/20170809171520/https://www.uniter.by/upload/iblock/725/725f5cc0f3323411be25ffb8f7a9e6be.pdf . dead .
  4. http://www.nativita.com/en/press-center/ofitsialnoe-otkrytie-nauchno-issledovatelskogo-kompleksa-nativita The official opening ceremony of NatiVita research complex was held on July 13, 2017